정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 541 | Active, not recruiting | SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults | SARS-CoV-2 Infection | Biological: 25 μg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) Drug: Sodium chloride, USP, for injection (0.9% NaCl) Biological: 50 μg SpFN_1B-06-PL + ALFQ (QS21 Adjuvant) |
Phase 1 | U.S. Army Medical Research and Development Command, Walter Reed Army Institute of Research (WRAIR), Henry M. Jackson Foundation for the Advancement of Military Medicine | FED | 29 | All | 18 Years ~ 55 Years | WRAIR Clinical Trials Center, Silver Spring, Maryland, United States |
| 540 | Terminated | Saved From COVID-19 | Coronavirus Infection | Drug: Chloroquine Drug: Placebo oral tablet |
Phase 2 | Columbia University | OTHER | 8 | All | 18 Years | Columbia University Irving Medical Center/NYP, New York, New York, United States |
| 539 | Active, not recruiting | SCB-2019 as COVID-19 Vaccine | COVID-19 | Biological: SCB-2019 Biological: SCB-2019 with AS03 adjuvant Biological: SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant |
Phase 1 | Clover Biopharmaceuticals AUS Pty Ltd | INDUSTRY | 150 | All | 18 Years ~ 75 Years | Linear Clinical Research Ltd, Nedlands, Western Australia, Australia |
| 538 | Terminated | SCIL-1Ra in COVID-19 Feasibility & PK/PD | COVID-19 | Drug: Anakinra 100Mg/0.67Ml Inj Syringe | Phase 2 | University of Manchester | OTHER | 5 | All | 18 Years | Manchester Univesity NHS Foundation Trust, Manchester, United Kingdom Salford Royal NHS Foundation Tust, Salford, United Kingdom |
| 537 | Recruiting | SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival | Hypoxic Respiratory Failure | Drug: Isoflurane Inhalant Product Drug: Sevoflurane inhalant product |
Phase 3 | Sunnybrook Health Sciences Centre | OTHER | 752 | All | 18 Years | University of Alberta Hospital, Edmonton, Alberta, Canada London Health Sciences Centre - University Hospital, London, Ontario, Canada London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada The Ottawa Hospital, Ottawa, Ontario, Canada Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada University Health Network - Toronto General Hospital, Toronto, Ontario, Canada University Health Network - Toronto Western Hopsital, Toronto, Ontario, Canada Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada McGill University Health Centre - Royal Victoria Hospital, Montreal, Quebec, Canada Hopital Sacre-Coeur de Montreal, Montreal, Quebec, Canada Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ), Quebec, Quebec, Canada Universite de Sherbrooke, Sherbrooke, Quebec, Canada |
| 536 | Terminated | Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection | COVID19 Infection | Drug: Sevoflurane Drug: Propofol |
Phase 4 | Fundacion para la Investigacion del Hospital Clinico de Valencia | OTHER | 19 | All | 18 Years ~ 99 Years | Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain Hospital Universitario Ramon y Cajal, Madrid, Spain Hospital Universitario La Paz, Madrid, Spain Hospital Clinico Universitario de Valencia, Valencia, Spain Hospital General Universitario de Valencia, Valencia, Spain |
| 535 | Withdrawn | Selective Estrogen Modulation and Melatonin in Early COVID-19 | Covid19 | Drug: Toremifene Drug: Melatonin Other: Placebo |
Phase 2 | Reena Mehra, MD | OTHER | 0 | All | 18 Years |
